Patients with intractable inflammatory bowel diseases (IBD) are increasingly being treated with anti-tumor necrosis factor (TNF) agents and are at increased risk of developing tuberculosis (TB). Therefore, diagnosis and treatment of latent TB infection (LTBI) is recommended in patients due to the initiation of anti-TNF therapy. Traditionally, LTBI has been diagnosed on the basis of clinical factors and a tuberculin skin test. Recently, interferon-gamma releasing assays (IGRAs) that can detect TB infection have become available. Considering the high-risk of developing TB in patients on anti-TNF therapy, the use of both a tuberculin skin test and an IGRA should be considered to detect and treat LTBI in patients with IBD due to the initiation of anti-TNF therapy. The traditional LTBI treatment regimen has consisted of isoniazid monotherapy for 9 months. However, shorter regimens such as 4 months of rifampicin or 3 months of isoniazid/rifampicin have been used increasingly to improve treatment completion rates. In this review, the incidence of TB and the prevalence of LTBI in patients with IBD will be briefly described, as well as methods for diagnosing latent and active TB before anti-TNF therapy, current LTBI treatment regimens, recommendations for managing TB that develops during anti-TNF therapy, the necessity of regular monitoring to detect new TB infection, and the re-initiation of anti-TNF therapy in patients who develop TB.

Citations

Citations to this article as recorded by  

• Infection screening prior to Ocrelizumb initiation in patients with Multiple Sclerosis (MS): Concise clinical recommendation based on a modified Delphi consensus on behalf of the Iranian MS –infectious disease group
  Sepideh Paybast, Marzie Abutorabi-zarchi, Fereshteh Ashtari, Seyyed Mohammad Baghbanian, Nahid Beladi Moghadam, Zahra Ebadi, Atefeh Eidi, Mehran Ghaffari, Hamidreza Ghalyanchi Langroodi, Hora Heidari, Samaneh Hosseini, Hoda Kamali, Nastaran Majdinasab, Fa
  Multiple Sclerosis and Related Disorders.2026; 105: 106824.     CrossRef
• Risk of tuberculosis with anti-TNF therapy in Indian patients with inflammatory bowel disease despite negative screening
  Suprabhat Giri, Sukanya Bhrugumalla, Akash Shukla, Sagar Gangadhar, Srujan Reddy, Sumaswi Angadi, Leela Shinde, Aditya Kale
  Arab Journal of Gastroenterology.2025; 26(1): 33.     CrossRef
• The Impact of Body Mass Index on Latent Tuberculosis Infection: Combined Assessment in People Living with HIV
  Jingxian Ning, Peng Lu, Yuchen Pan, Yilin Lian, Yu Zhang, Wenxin Jiang, Leonardo Martinez, Limei Zhu, Qiao Liu
  Pathogens.2025; 14(11): 1078.     CrossRef
• Tumor Necrosis Alpha (TNF-α) Antagonists Used in Chronic Inflammatory Rheumatic Diseases: Risks and their Minimization Measures
  Rim Lakhmiri, Yahia Cherrah, Samira Serragui
  Current Drug Safety.2024; 19(4): 431.     CrossRef
• Features of detection of latent tuberculosis infection in patients with inflammatory intestinal diseases
  Gylystan Babaeva, Keniul Kerimova, Gamar Ahmedzade
  Bulletin of the Academy of Sciences of Moldova. Medical Sciences.2024; 77(3): 47.     CrossRef
• Screening of latent tuberculosis infection among patients with diabetes mellitus from a high-burden area in Brazil
  Amanda Vital Torres, Raquel da Silva Corrêa, Maria de Fátima Bevilacqua, Luana Cristina França do Prado, Flavia Miranda Gomes de Constantino Bandeira, Luciana Silva Rodrigues, Marilia Brito Gomes
  Frontiers in Clinical Diabetes and Healthcare.2022;[Epub]     CrossRef
• Comparison of Interferon-Gamma Release Assay and Tuberculin Skin Test for the Screening of Latent Tuberculosis in Inflammatory Bowel Disease Patients: Indian Scenario
  Alok Kumar Mantri, Priti Meena, Amarender Singh Puri, Ajay Kumar, Sanjeev Sachdeva, Siddharth Srivastava, K. Arivarasan, Shivakumar Varakanahali, Jos R. Lapa e Silva
  Tuberculosis Research and Treatment.2021; 2021: 1.     CrossRef
• Risk and characteristics of tuberculosis after anti-tumor necrosis factor therapy for inflammatory bowel disease: a hospital-based cohort study from Korea
  Jae Yong Lee, Kyunghwan Oh, Hee Seung Hong, Kyuwon Kim, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Ho-Su Lee, Kyung-Wook Jo, Sang Hyoung Park
  BMC Gastroenterology.2021;[Epub]     CrossRef
• Risk stratification and management of QuantiFERON-positive solid-organ living donors
  Jean Gibb, Darren Wong
  Current Opinion in Organ Transplantation.2020; 25(4): 351.     CrossRef
• Variations of tuberculin skin test in patients with rheumatologic disorders and under anti-TNF treatment
  Tayfun Özdemir, Serpil Tuna, Özlem Karataş, Mehmet İhsan Arman
  Journal of Surgery and Medicine.2019;[Epub]     CrossRef
• Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti‐tumor necrosis factor treatment. Part 1: Risk assessment
  Dong II Park, Tadakazu Hisamatsu, Minhu Chen, Siew Chien Ng, Choon Jin Ooi, Shu Chen Wei, Rupa Banerjee, Ida Normiha Hilmi, Yoon Tae Jeen, Dong Soo Han, Hyo Jong Kim, Zhihua Ran, Kaichun Wu, Jiaming Qian, Pin‐Jin Hu, Katsuyoshi Matsuoka, Akira Andoh, Yasu
  Journal of Gastroenterology and Hepatology.2018; 33(1): 20.     CrossRef
• A Surprising Granulomatous Cheilitis
  Chloé Charpentier, Diane Kottler, Charlotte Fite, Anne-Laure Pelletier, Lydia Deschamps, Vincent Descamps
  Gastroenterology.2018; 154(5): 1239.     CrossRef
• Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management
  Dong Il Park, Tadakazu Hisamatsu, Minhu Chen, Siew Chien Ng, Choon Jin Ooi, Shu Chen Wei, Rupa Banerjee, Ida Normiha Hilmi, Yoon Tae Jeen, Dong Soo Han, Hyo Jong Kim, Zhihua Ran, Kaichun Wu, Jiaming Qian, Pin-Jin Hu, Katsuyoshi Matsuoka, Akira Andoh, Yasu
  Intestinal Research.2018; 16(1): 17.     CrossRef
• Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti‐tumor necrosis factor treatment. Part 2: Management
  Dong Il Park, Tadakazu Hisamatsu, Minhu Chen, Siew Chien Ng, Choon Jin Ooi, Shu Chen Wei, Rupa Banerjee, Ida Normiha Hilmi, Yoon Tae Jeen, Dong Soo Han, Hyo Jong Kim, Zhihua Ran, Kaichun Wu, Jiaming Qian, Pin‐Jin Hu, Katsuyoshi Matsuoka, Akira Andoh, Yasu
  Journal of Gastroenterology and Hepatology.2018; 33(1): 30.     CrossRef
• Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment
  Dong Il Park, Tadakazu Hisamatsu, Minhu Chen, Siew Chien Ng, Choon Jin Ooi, Shu Chen Wei, Rupa Banerjee, Ida Normiha Hilmi, Yoon Tae Jeen, Dong Soo Han, Hyo Jong Kim, Zhihua Ran, Kaichun Wu, Jiaming Qian, Pin-Jin Hu, Katsuyoshi Matsuoka, Akira Andoh, Yasu
  Intestinal Research.2018; 16(1): 4.     CrossRef
• Second Korean guidelines for the management of ulcerative colitis
  Chang Hwan Choi, Won Moon, You Sun Kim, Eun Soo Kim, Bo-In Lee, Yunho Jung, Yong Sik Yoon, Heeyoung Lee, Dong Il Park, Dong Soo Han
  Intestinal Research.2017; 15(1): 7.     CrossRef
• Second Korean Guideline for the Management of Ulcerative Colitis
  Chang Hwan Choi, Won Moon, You Sun Kim, Eun Soo Kim, Bo-In Lee, Yunho Jung, Yong Sik Yoon, Heeyoung Lee, Dong Il Park, Dong Soo Han
  The Korean Journal of Gastroenterology.2017; 69(1): 1.     CrossRef
• Decreased CD8+CD28+/CD8+CD28– T cell ratio can sensitively predict poor outcome for patients with complicated Crohn disease
  Shi-xue Dai, Hong-xiang Gu, Qian-yi Lin, Yan-kun Wu, Xiao-yan Wang, Shao-zhuo Huang, Tiao-si Xing, Min-hua Chen, Qing-fang Zhang, Zhong-wen Zheng, Wei-hong Sha
  Medicine.2017; 96(26): e7247.     CrossRef
• Serial Tuberculosis Screening in Inflammatory Bowel Disease Patients Receiving Anti-TNFα Therapy
  Cândida Abreu, Joana Afonso, Cláudia Camila Dias, Rogério Ruas, António Sarmento, Fernando Magro
  Journal of Crohn's and Colitis.2017; 11(10): 1223.     CrossRef
• Association between TNF -308G/A polymorphism and susceptibility to pulmonary tuberculosis in the Lur population of Iran
  Farhad Shahsavar, Ali Mohammad Varzi, Alireza Azargoon
  Asian Pacific Journal of Tropical Biomedicine.2016; 6(1): 80.     CrossRef
• Differences in Clinical Manifestations according to the Positivity of Interferon-γ Assay in Patients with Intestinal Tuberculosis
  Hye Jin Jung, Young-Ho Kim, You Sun Kim, Seong Yeon Jeong, Sung Won Park, Ji Yeon Seo, Hyemi Jung, Jong Pil Im, Ji Won Kim, Sung Noh Hong, Kuk Lae Lee
  Gut and Liver.2016; 10(4): 649.     CrossRef
• Reactivation tuberculosis: role of surveillance
  Andrew R. DiNardo, Elizabeth Guy
  Expert Review of Anti-infective Therapy.2016; 14(5): 501.     CrossRef
• Rectal tuberculosis after infliximab therapy despite negative screening for latent tuberculosis in a patient with ulcerative colitis
  Jatinderpal Singh, Amarender S Puri, Sanjeev Sachdeva, Puja Sakhuja, Kulandaivelu Arivarasan
  Intestinal Research.2016; 14(2): 183.     CrossRef
• Clinical features of active tuberculosis that developed during anti-tumor necrosis factor therapy in patients with inflammatory bowel disease
  Jang Wook Lee, Chang Hwan Choi, Ji Hoon Park, Jeong Wook Kim, Sang Bum Kang, Ja Seol Koo, Young-Ho Kim, You Sun Kim, Young Eun Joo, Sae Kyung Chang
  Intestinal Research.2016; 14(2): 146.     CrossRef
• How Should We Manage Latent Tuberculosis Infection in Patients Receiving Anti-TNF-α Drugs: Literature Review
  Hamid Reza Naderi, Fereshte Sheybani, Susan Rezaei Pajand
  Iranian Red Crescent Medical Journal.2016;[Epub]     CrossRef
• Efficacy and Safety of Infliximab Therapy and Predictors of Response in Korean Patients with Crohn's Disease: A Nationwide, Multicenter Study
  Chang Hwan Choi, In Do Song, Young-Ho Kim, Ja Seol Koo, You Sun Kim, Joo Sung Kim, Nayoung Kim, Eun Soo Kim, Jae Hak Kim, Ji Won Kim, Tae Oh Kim, Hyun Soo Kim, Hyo Jong Kim, Young Sook Park, Dong Il Park, Soo Jung Park, Hyun Joo Song, Sung Jae Shin, Suk-K
  Yonsei Medical Journal.2016; 57(6): 1376.     CrossRef
• Infektiöse Komplikationen der immunsuppressiven Therapie
  T. Feldkamp, O. Witzke
  Der Nephrologe.2015; 10(1): 38.     CrossRef
• Inflammatory Bowel Disease Cohort Studies in Korea: Present and Future
  Jung Won Lee, Jong Pil Im, Jae Hee Cheon, You Sun Kim, Joo Sung Kim, Dong Soo Han
  Intestinal Research.2015; 13(3): 213.     CrossRef
• Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments
  Bruno Rafael Ramos de Mattos, Maellin Pereira Gracindo Garcia, Julia Bier Nogueira, Lisiery Negrini Paiatto, Cassia Galdino Albuquerque, Caique Lopes Souza, Luís Gustavo Romani Fernandes, Wirla Maria da Silva Cunha Tamashiro, Patricia Ucelli Simioni, Even
  Mediators of Inflammation.2015;[Epub]     CrossRef
• Diagnosis and Treatment of Latent Tuberculosis Infection due to Initiation of Anti-TNF Therapy
  Tae Sun Shim
  Tuberculosis and Respiratory Diseases.2014; 76(6): 261.     CrossRef